BIO’s 2012 Fall IPCC Conference event on November 12-14 gathers biotech in-house counsels to provide and discuss relevant IP developments. The Honorable Jimmie V. Reyna, Circuit Judge for the United States Court of Appeals for the Federal Circuit keynotes this year’s program along with the Honorable Judge Sally Gardner Lane, Administrative Patent Judge, Trial Division, Board of Patent Appeals and Interferences.
Find program topics and speakers below. Click here for the full agenda.
Picking the Best Tools From Your Tool Box: Responding Strategically to Freedom To Operate Obstacles Under the AIA
Eldora L. Ellison, Ph.D., Director, Sterne, Kessler, Goldstein & Fox
Eric K. Steffe, Director, Sterne, Kessler, Goldstein & Fox
Todd Spalding, Assistant General Counsel, Bristol-Myers Squibb
The Unitary European Patent
Hugh Goodfellow, Partner, Carpmaels & Ransford
Cases To Watch
John F. Murphy, PhD, Associate, Woodcock Washburn LLP
Amy Nelson, Associate Solicitor, U.S. Patent & Trademark Office
Erica Olson, Senior Counsel, Amgen Inc.
John Paolino, Chief IP Law Counsel, Orthofix International N.V.
Pitfalls and Perplexities of Biotech Patenting
Peter Knudsen, Ph.D., Partner, Woodcock Washburn LLP
Paul Golian, Assistant General Counsel, Bristol-Myers Squibb
William F. Smith, Of Counsel, Woodcock Washburn LLP and former Administrative Patent Judge, U.S. Patent & Trademark Office
Jean C. Witz, Supervisory Patent Examiner, Technology Center 1600, U.S. Patent & Trademark Office
How Do You Infringe a Pharmaceutical Method Claim?
Howard W. Levine, Partner, Finnegan, Henderson, Farabow, Garrett & Dunner LLP
Robert F. Shaffer, Partner, Finnegan, Henderson, Farabow, Garrett & Dunner LLP
Charles M. Kinzig, Vice President, Corporate IP, GlaxoSmithKline
Navigating Through a Storm: Challenging Patent Term Adjustment Regulations
Jennifer Johnson, Ph.D., Associate, Finnegan, Henderson, Farabow, Garrett & Dunnr LLP
Jeffrey A. Lamken, Partner, Molo Lamken
The Trade Secret Minefield
Eric J. Marandett, Partner, Choate Hall & Stewart LLP
Philip Chase, General Counsel, Adimab
Daniel Darnley, Vice President & Chief IP Counsel, Millennium: The Takeda Oncology Company
Will Prometheus & Myriad Change the World? What Do They Really Mean For the Biotechnology Industry?
Brenda Herschbach Jarrell, Ph.D., Partner, Choate Hall & Stewart LLP
Karla Weyand, Managing IP Counsel, Siemens Corp.
Richard Marsh, Executive Vice President, General Counsel & Secretary, Myriad Genetics, Inc.